A novel anticancer agent SNG1153 inhibits growth of lung cancer stem/progenitor cells
Metrics: PDF 1483 views | HTML 406 views | ?
Shiyang Liu1,*, Yuming Guo2,*, Jing Wang2, Hai Zhu2, Yuqing Han2, Mingji Jin2, Jun Wang2, Congya Zhou2, Junfeng Ma1, Qingcong Lin2, Zhaoyi Wang2, Kun Meng2, Xueqi Fu1
1School of Life Sciences, Jilin University, Changchun, P.R. China
2Beijing Shenogen Biomedical Co., Ltd, Beijing, P.R. China
*These authors contributed equally to this work
Kun Meng, email: firstname.lastname@example.org
Xueqi Fu, email: email@example.com
Keywords: SNG1153, lung cancer, CSC, tumorsphere, β-catenin
Received: December 01, 2015 Accepted: May 20, 2016 Published: June 02, 2016
Lung cancer is the leading cause of cancer-related death in both men and women. Lung cancer contains a small population of cancer cells with stem-like features known as cancer stem cells (CSCs). CSCs are often more resistant to current therapeutic treatments. Thus, it is urgent to develop a novel agent that is able to inhibit CSCs growth. In this study, we examined the ability of SNG1153, a novel chemical agent to inhibit the growth of lung CSCs. We found that SNG1153 inhibited growth and induced apoptosis in established lung cancer cells. We also found that SNG1153 inhibited the tumorsphere formation and decreased CD133-positive (lung CSC marker) cancer cells. SNG1153 was able to attenuate tumor formation in NOD/SCID (non-obese diabetic/severe combined immunodeficient) mice injected with lung tumorsphere cells. We further demonstrated that SNG1153 induced β-catenin phosphorylation and down-regulated β-catenin. Our results thus demonstrate that SNG1153 effectively inhibits the growth of lung CSCs and suggest that SNG1153 may be a novel therapeutic agent to treat human lung cancer.
Primary Contact _
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.